We have successfully produced anti-podoplanin CasMabs, such as LpMab-2 [25] and LpMab-23 [28] that specifically recognize cancer-type podoplanin in tumor tissues and not in normal-type podoplanin, which is expressed in lymphatic vessels. Here, PDPN is linked to cancer.